New hope for stomach cancer patients when first treatment fails
NCT ID NCT07139587
First seen Sep 30, 2025 · Last updated May 24, 2026 · Updated 30 times
Summary
This study tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer whose first treatment stopped working or caused side effects. The goal is to see if this new combo can shrink tumors and help people live longer. About 30 adults aged 18-75 will receive the treatment every 3 weeks until their disease gets worse or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hebei General Hospital
Shijiazhuang, Hebei, 050000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.